Next generation of antimicrobial peptides as molecular targeted medicines

Journal of Bioscience and Bioengineering

Volumn 114, Issue 4, 2012, Pages 365-370

  Aoki, Wataru ^a,b   Kuroda, Kouichi ^b   Ueda, Mitsuyoshi ^b  

^a JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Activity regulation; Antibiotic; Antimicrobial peptide; Defensin; Drug delivery; Specifically targeted antimicrobial peptides (STAMPs)

Indexed keywords

ACTIVITY REGULATION; ANTI-MICROBIAL ACTIVITY; ANTIMICROBIAL PEPTIDE; BROAD SPECTRUM; CONVENTIONAL DRUGS; DEFENSINS; GRAM-NEGATIVE BACTERIA; HEMOLYTIC ACTIVITY; HUMAN BODIES; INTEGRAL PART; LIVING ENVIRONMENT; MICROBIOTAS; MICROFLORA; MUCOSAL SURFACE; NOVEL ANTIBIOTICS; PATHOGENIC ORGANISMS; QUALITY-OF-LIFE;

BIOLOGY; DRUG DELIVERY; POLYPEPTIDES; VIRUSES;

ANTIBIOTICS;

ADEPANTIN 1; CLAVANIN A; DEFENSIN; GRAMICIDIN S; LIPOPOLYSACCHARIDE; MAGAININ 2; MELITTIN; ONCOCIN; POLYPEPTIDE ANTIBIOTIC AGENT; SPECIFICALLY TARGETED ANTIMICROBIAL PEPTIDE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BINDING SITE; CELL MEMBRANE; DRUG DESIGN; ENTEROBACTERIACEAE; EPITHELIUM CELL; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HONEYBEE; HOSPITAL INFECTION; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NEUTROPHIL; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS MUTANS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; DEFENSINS; DESIGNER DRUGS; FUNGI; HUMANS; MOLECULAR TARGETED THERAPY; NEUTROPHILS;

FUNGI; NEGIBACTERIA; POSIBACTERIA;

EID: 84865973489     PISSN: 13891723     EISSN: 13474421     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2012.05.001     Document Type: Review

References (89)

1. Demain A.L., Sanchez S. Microbial drug discovery: 80 years of progress. J. Antibiot. 2009, 62:5-16.
2. Schatz A., Bugie E., Waksman S.A. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Exp. Biol. Med. 1944, 55:66-69.
3. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
4. Morris S., Bai G.H., Suffys P., Portillo-Gomez L., Fairchok M., Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J. Infect. Dis. 1995, 171:954-960.
5. Cohen M.L. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 1992, 257:1050-1055.
6. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 2006, 50:43-48.
7. Hiramatsu K., Aritaka N., Hanaki H., Kawasaki S., Hosoda Y., Hori S., Fukuchi Y., Kobayashi I. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997, 350:1670-1673.
8. Ament P.W., Jamshed N., Horne J.P. Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections. Am. Fam. Physician 2002, 65:663-670.
9. Sanchez Garcia M., De la Torre M.A., Morales G., Pelaez B., Tolon M.J., Domingo S., Candel F.J., Andrade R., Arribi A., Garcia N., other 3 authors Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010, 303:2260-2264.
10. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA 1987, 84:5449-5453.
11. Giuliani A., Pirri G., Nicoletto S.F. Antimicrobial peptides: an overview of a promising class of therapeutics. Cent. Eur. J. Biol. 2007, 2:1-33.
12. Wakabayashi H., Hiratani T., Uchida K., Yamaguch H. Antifungal spectrum and fungicidal mechanism of an N-terminal peptide of bovine lactoferrin. J. Infect. Chemother. 1996, 1:185-189.
13. Yamauchi K., Tomita M., Giehl T.J., Ellison R.T. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect. Immun. 1993, 61:719-728.
14. Mygind P.H., Fischer R.L., Schnorr K.M., Hansen M.T., Sonksen C.P., Ludvigsen S., Raventos D., Buskov S., Christensen B., De Maria L., other 10 authors Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 2005, 437:975-980.
15. Bechinger B. The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy. Biochim. Biophys. Acta 1999, 1462:157-183.
16. Mani R., Cady S.D., Tang M., Waring A.J., Lehrer R.I., Hong M. Membrane-dependent oligomeric structure and pore formation of a beta-hairpin antimicrobial peptide in lipid bilayers from solid-state NMR. Proc. Natl. Acad. Sci. USA 2006, 103:16242-16247.
17. Gifford J.L., Hunter H.N., Vogel H.J. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol. Life Sci. 2005, 62:2588-2598.
18. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat. Rev. Microbiol. 2005, 3:238-250.
19. Nguyen L.T., Haney E.F., Vogel H.J. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011, 29:464-472.
20. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415:389-395.
21. Jenssen H., Hamill P., Hancock R.E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 2006, 19:491-511.
22. Dathe M., Wieprecht T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim. Biophys. Acta 1999, 1462:71-87.
23. Matsuzaki K., Sugishita K., Fujii N., Miyajima K. Molecular basis for membrane selectivity of an antimicrobial peptide, magainin 2. Biochemistry 1995, 34:3423-3429.
24. Ganz T. Defensins and host defense. Science 1999, 286:420-421.
25. Arvola T., Laiho K., Torkkeli S., Mykkanen H., Salminen S., Maunula L., Isolauri E. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999, 104:e64.
26. Doron S.I., Hibberd P.L., Gorbach S.L. Probiotics for prevention of antibiotic-associated diarrhea. J. Clin. Gastroenterol. 2008, 42:58-63.
27. Danna P.L., Urban C., Bellin E., Rahal J.J. Role of Candida in pathogenesis of antibiotic-associated diarrhoea in elderly inpatients. Lancet 1991, 337:511-514.
28. Giannella R.A. Antibiotic-associated diarrhea and Clostridium difficile colitis: an update. Rev. Esp. Enferm. Dig. 2001, 93:535-543.
29. Hancock R.E., Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006, 24:1551-1557.
30. Brown K.L., Hancock R.E. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 2006, 18:24-30.
31. Gill S.R., Pop M., Deboy R.T., Eckburg P.B., Turnbaugh P.J., Samuel B.S., Gordon J.I., Relman D.A., Fraser-Liggett C.M., Nelson K.E. Metagenomic analysis of the human distal gut microbiome. Science 2006, 312:1355-1359.
32. Dewhirst F.E., Chen T., Izard J., Paster B.J., Tanner A.C., Yu W.H., Lakshmanan A., Wade W.G. The human oral microbiome. J. Bacteriol. 2010, 192:5002-5017.
33. Turnbaugh P.J., Ley R.E., Hamady M., Fraser-Liggett C.M., Knight R., Gordon J.I. The human microbiome project. Nature 2007, 449:804-810.
34. Goldman M.J., Anderson G.M., Stolzenberg E.D., Kari U.P., Zasloff M., Wilson J.M. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997, 88:553-560.
35. Putsep K., Carlsson G., Boman H.G., Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 2002, 360:1144-1149.
36. Diamond G., Beckloff N., Ryan L.K. Host defense peptides in the oral cavity and the lung: similarities and differences. J. Dent. Res. 2008, 87:915-927.
37. Dale B.A., Fredericks L.P. Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr. Issues Mol. Biol. 2005, 7:119-133.
38. Gorr S.-U. Antimicrobial peptides of the oral cavity. Periodontology 2000 2009, 51:152-180.
39. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 2003, 3:710-720.
40. Cole A.M., Hong T., Boo L.M., Nguyen T., Zhao C., Bristol G., Zack J.A., Waring A.J., Yang O.O., Lehrer R.I. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. USA 2002, 99:1813-1818.
41. Tang Y.Q., Yuan J., Osapay G., Osapay K., Tran D., Miller C.J., Ouellette A.J., Selsted M.E. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science 1999, 286:498-502.
42. Ganz T., Selsted M.E., Szklarek D., Harwig S.S., Daher K., Bainton D.F., Lehrer R.I. Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Invest. 1985, 76:1427-1435.
43. Ganz T., Lehrer R.I. Defensins. Pharmacol. Ther. 1995, 66:191-205.
44. Rice W.G., Ganz T., Kinkade J.M., Selsted M.E., Lehrer R.I., Parmley R.T. Defensin-rich dense granules of human neutrophils. Blood 1987, 70:757-765.
45. Cowland J.B., Borregaard N. The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. J. Leukoc. Biol. 1999, 66:989-995.
46. Yount N.Y., Wang M.S., Yuan J., Banaiee N., Ouellette A.J., Selsted M.E. Rat neutrophil defensins. Precursor structures and expression during neutrophilic myelopoiesis. J. Immunol. 1995, 155:4476-4484.
47. Faurschou M., Sorensen O.E., Johnsen A.H., Askaa J., Borregaard N. Defensin-rich granules of human neutrophils: characterization of secretory properties. Biochim. Biophys. Acta 2002, 1591:29-35.
48. Ganz T. Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect. Immun. 1987, 55:568-571.
49. Ganz T., Oren A., Lehrer R.I. Defensins: microbicidal and cytotoxic peptides of mammalian host defense cells. Med. Microbiol. Immunol. 1992, 181:99-105.
50. Faurschou M., Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 2003, 5:1317-1327.
51. Sengelov H., Kjeldsen L., Borregaard N. Control of exocytosis in early neutrophil activation. J. Immunol. 1993, 150:1535-1543.
52. Joly S., Maze C., McCray P.B., Guthmiller J.M. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J. Clin. Microbiol. 2004, 42:1024-1029.
53. Dale B.A., Kimball J.R., Krisanaprakornkit S., Roberts F., Robinovitch M., O'Neal R., Valore E.V., Ganz T., Anderson G.M., Weinberg A. Localized antimicrobial peptide expression in human gingiva. J. Periodontal. Res. 2001, 36:285-294.
54. Sawaki K., Mizukawa N., Yamaai T., Fukunaga J., Sugahara T. Immunohistochemical study on expression of alpha-defensin and beta-defensin-2 in human buccal epithelia with candidiasis. Oral Dis. 2002, 8:37-41.
55. Chung W.O., Dale B.A. Innate immune response of oral and foreskin keratinocytes: utilization of different signaling pathways by various bacterial species. Infect. Immun. 2004, 72:352-358.
56. Liu L., Roberts A.A., Ganz T. By IL-1 signaling, monocyte-derived cells dramatically enhance the epidermal antimicrobial response to lipopolysaccharide. J. Immunol. 2003, 170:575-580.
57. Garcia J.R., Krause A., Schulz S., Rodriguez-Jimenez F.J., Kluver E., Adermann K., Forssmann U., Frimpong-Boateng A., Bals R., Forssmann W.G. Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J. 2001, 15:1819-1821.
58. Sorensen O.E., Cowland J.B., Theilgaard-Monch K., Liu L., Ganz T., Borregaard N. Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J. Immunol. 2003, 170:5583-5589.
59. Bals R., Goldman M.J., Wilson J.M. Mouse beta-defensin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. Infect. Immun. 1998, 66:1225-1232.
60. Glukhov E., Stark M., Burrows L.L., Deber C.M. Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J. Biol. Chem. 2005, 280:33960-33967.
61. Umeyama M., Kira A., Nishimura K., Naito A. Interactions of bovine lactoferricin with acidic phospholipid bilayers and its antimicrobial activity as studied by solid-state NMR. Biochim. Biophys. Acta 2006, 1758:1523-1528.
62. Katsu T., Kuroko M., Morikawa T., Sanchika K., Fujita Y., Yamamura H., Uda M. Mechanism of membrane damage induced by the amphipathic peptides gramicidin S and melittin. Biochim. Biophys. Acta 1989, 983:135-141.
63. Steiner H., Hultmark D., Engstrom A., Bennich H., Boman H.G. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 1981, 292:246-248.
64. Chou H.T., Kuo T.Y., Chiang J.C., Pei M.J., Yang W.T., Yu H.C., Lin S.B., Chen W.J. Design and synthesis of cationic antimicrobial peptides with improved activity and selectivity against Vibrio spp. Int. J. Antimicrob. Agents 2008, 32:130-138.
65. Juretic D., Vukicevic D., Petrov D., Novkovic M., Bojovic V., Lucic B., Ilic N., Tossi A. Knowledge-based computational methods for identifying or designing novel, non-homologous antimicrobial peptides. Eur. Biophys. J. 2011, 40:371-385.
66. Juretic D., Vukicevic D., Ilic N., Antcheva N., Tossi A. Computational design of highly selective antimicrobial peptides. J. Chem. Inf. Model 2009, 49:2873-2882.
67. Gaynes R., Edwards J.R. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 2005, 41:848-854.
68. Peleg A.Y., Hooper D.C. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med. 2010, 362:1804-1813.
69. Su Y., Waring A.J., Ruchala P., Hong M. Structures of beta-hairpin antimicrobial protegrin peptides in lipopolysaccharide membranes: mechanism of gram selectivity obtained from solid-state nuclear magnetic resonance. Biochemistry 2011, 50:2072-2083.
70. Muhle S.A., Tam J.P. Design of Gram-negative selective antimicrobial peptides. Biochemistry 2001, 40:5777-5785.
71. Scott M.G., Rosenberger C.M., Gold M.R., Finlay B.B., Hancock R.E. An alpha-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression. J. Immunol. 2000, 165:3358-3365.
72. Casteels P., Ampe C., Jacobs F., Vaeck M., Tempst P. Apidaecins: antibacterial peptides from honeybees. EMBO J. 1989, 8:2387-2391.
73. Bulet P., Dimarcq J.L., Hetru C., Lagueux M., Charlet M., Hegy G., Van Dorsselaer A., Hoffmann J.A. A novel inducible antibacterial peptide of Drosophila carries an O-glycosylated substitution. J. Biol. Chem. 1993, 268:14893-14897.
74. Knappe D., Piantavigna S., Hansen A., Mechler A., Binas A., Nolte O., Martin L.L., Hoffmann R. Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens. J. Med. Chem. 2010, 53:5240-5247.
75. Shamova O., Brogden K.A., Zhao C., Nguyen T., Kokryakov V.N., Lehrer R.I. Purification and properties of proline-rich antimicrobial peptides from sheep and goat leukocytes. Infect. Immun. 1999, 67:4106-4111.
76. He J., Yarbrough D.K., Kreth J., Anderson M.H., Shi W., Eckert R. Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans. Antimicrob. Agents Chemother. 2010, 54:2143-2151.
77. Eckert R., Qi F., Yarbrough D.K., He J., Anderson M.H., Shi W. Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp. Antimicrob. Agents Chemother. 2006, 50:1480-1488.
78. Banas J.A. Virulence properties of Streptococcus mutans. Front Biosci. 2004, 9:1267-1277.
79. Loesche W.J. Role of Streptococcus mutans in human dental decay. Microbiol. Rev. 1986, 50:353-380.
80. Eckert R., He J., Yarbrough D.K., Qi F., Anderson M.H., Shi W. Targeted killing of Streptococcus mutans by a pheromone-guided " smart" antimicrobial peptide. Antimicrob. Agents Chemother. 2006, 50:3651-3657.
81. Li L.N., Guo L.H., Lux R., Eckert R., Yarbrough D., He J., Anderson M., Shi W.Y. Targeted antimicrobial therapy against Streptococcus mutans establishes protective non-cariogenic oral biofilms and reduces subsequent infection. Int. J. Oral. Sci. 2010, 2:66-73.
82. Svensater G., Sjogreen B., Hamilton I.R. Multiple stress responses in Streptococcus mutans and the induction of general and stress-specific proteins. Microbiology 2000, 146:107-117.
83. Lee I.H., Zhao C., Cho Y., Harwig S.S., Cooper E.L., Lehrer R.I. Clavanins, alpha-helical antimicrobial peptides from tunicate hemocytes. FEBS Lett. 1997, 400:158-162.
84. Li L., He J., Eckert R., Yarbrough D., Lux R., Anderson M., Shi W. Design and characterization of an acid-activated antimicrobial peptide. Chem. Biol. Drug Des. 2009, 75:127-132.
85. Tsuboi R., Matsuda K., Ko I.J., Ogawa H. Correlation between culture medium pH, extracellular proteinase activity, and cell growth of Candida albicans in insoluble stratum corneum-supplemented media. Arch. Dermatol. Res. 1989, 281:342-345.
86. Gottler L.M., Ramamoorthy A. Structure, membrane orientation, mechanism, and function of pexiganan-a highly potent antimicrobial peptide designed from magainin. Biochim. Biophys. Acta 2009, 1788:1680-1686.
87. Bulmus V., Ding Z., Long C.J., Stayton P.S., Hoffman A.S. Site-specific polymer-streptavidin bioconjugate for pH-controlled binding and triggered release of biotin. Bioconjug. Chem. 2000, 11:78-83.
88. Kim J.J., Park K. Modulated insulin delivery from glucose-sensitive hydrogel dosage forms. J. Control. Release 2001, 77:39-47.
89. Fogueri L.R., Singh S. Smart polymers for controlled delivery of proteins and peptides: a review of patents. Recent Pat. Drug Deliv. Formul. 2009, 3:40-48.